Merck partners with Mayo Clinic for AI drug discovery, posts positive ENFLONSIA data
Merck & Co has partnered with Mayo Clinic to integrate AI, advanced analytics and multimodal clinical-genomic data for target identification and early development across dermatology, neurology and gastroenterology. The company also reported positive two-season data for ENFLONSIA (clesrovimab) showing efficacy in infants under 2 at risk of severe RSV disease.
1. AI Collaboration Details
Merck & Co. has formed an R&D alliance with Mayo Clinic to leverage AI, advanced analytics and multimodal clinical-genomic datasets combined with MSD’s virtual cell technologies for improved target identification and early-stage decision-making. The partnership grants Merck access to de-identified clinical registries, biorepositories, medical imaging, lab results, molecular data and AI tools, initially focusing on atopic dermatitis, multiple sclerosis and inflammatory bowel disease.
2. ENFLONSIA RSV Data
Merck reported positive two-season data for ENFLONSIA (clesrovimab), demonstrating sustained RSV-neutralizing antibody levels and a well-tolerated safety profile in infants under two at increased risk for severe respiratory syncytial virus disease. The results support advancement of ENFLONSIA as a prophylactic option for high-risk pediatric populations.